UCHL3

PF3D7_1460400 (UCHL3) is an essential ubiquitin C-terminal hydrolase of Plasmodium falciparum that acts as a dual deubiquitinase and deNeddylase, removing both ubiquitin and Nedd8 modifications from substrates (PMID:17371404, PMID:20042598). Its catalytic behavior is governed by an active-site crossover loop that sterically restricts access of bulky adducts to the catalytic center; the loop is dispensable for catalysis per se, but enlarging it by mutation permits cleavage of substrates the wild-type enzyme cannot process, defining a size-restriction mechanism (PMID:19047059). Crystal structures of the apo enzyme and of a complex with the ubiquitin-based suicide substrate UbVME, together with modeling of the enzyme–Nedd8 complex, reveal the rigid crossover loop and the shared interactions that underlie dual ubiquitin/Nedd8 specificity, and the enzyme is essential for parasite survival (PMID:20042598). Functionally, inhibition of UCHL3 catalytic activity causes accumulation of polyubiquitinated proteins and disrupts blood-stage parasites, consistent with a role in ubiquitin removal from substrates (PMID:35042884), and its activity is required across multiple developmental stages including P. falciparum asexual blood stages and P. berghei sporozoites (PMID:37634761). The enzyme is druggable through distinct modalities: covalent fragments selective over human UCHL3/UCHL1 (PMID:37634761), constrained peptides that block the ubiquitin substrate-binding interface rather than the active site (PMID:38739798), and halofuginone, which binds UCHL3 directly and disrupts its influence on amino-acid biosynthetic protein expression (PMID:38923255). Beyond these findings, endogenous physiological substrates of UCHL3 in the parasite have not been defined in the available corpus.

1. 2007 High

   Establishing that the parasite enzyme is enzymatically active answered whether PF3D7_1460400 is a functional hydrolase and revealed it acts on two distinct ubiquitin-like modifiers.

   Evidence Activity-based covalent chemical probe and mass spectrometry on the recombinant enzyme

   PMID:17371404

   Open questions at the time

   • No endogenous substrates identified
   • Relative preference for ubiquitin versus Nedd8 not quantified
   • Cellular role not yet tested
2. 2008 High

   Mutagenesis of the active-site crossover loop resolved how the enzyme selects substrates, showing that steric restriction by the loop—not the catalytic machinery—limits which adducts can be cleaved.

   Evidence Sortagging, crossover-loop mutagenesis, and in vitro activity assays

   PMID:19047059

   Open questions at the time

   • Physiological consequence of size restriction unknown
   • Which native ubiquitin chain linkages are handled in vivo unclear
3. 2009 High

   Crystallographic capture of the enzyme with a suicide substrate provided the structural basis for both dual ubiquitin/Nedd8 specificity and substrate-size restriction, and genetic evidence established the gene as essential.

   Evidence X-ray structures (apo and UbVME complex), molecular dynamics of the enzyme–Nedd8 complex, and essentiality data

   PMID:20042598

   Open questions at the time

   • No experimental structure of the enzyme–Nedd8 complex
   • Essentiality mechanism (which pathway failure kills the parasite) undefined
4. 2022 Medium

   Small-molecule inhibition linked the enzyme's catalytic activity to a cellular phenotype, showing that blocking it causes polyubiquitin accumulation and disrupts late asexual blood-stage parasites.

   Evidence In vitro enzyme inhibition with two compounds, anti-plasmodial growth assay, and immunofluorescence phenotyping

   PMID:35042884

   Open questions at the time

   • Single lab
   • Off-target contributions to the growth phenotype not excluded
   • Specific accumulating substrates not identified
5. 2023 Medium

   Selective covalent fragments demonstrated that the enzyme's activity is required across life-cycle stages, extending its essentiality beyond blood stages to transmission-relevant sporozoites.

   Evidence Covalent fragment screen, selective enzyme inhibition over human orthologs, and growth assays in P. falciparum blood stages and P. berghei sporozoites

   PMID:37634761

   Open questions at the time

   • Single lab
   • In-parasite target engagement not directly confirmed
   • Stage-specific substrates unknown
6. 2024 Medium

   Two orthogonal chemical-biology studies defined druggable surfaces beyond the catalytic site—an exosite at the ubiquitin substrate-binding interface and a halofuginone-binding pocket—clarifying how the enzyme can be inhibited allosterically.

   Evidence RaPID mRNA display peptides with NMR mapping and deubiquitinase assays [#5]; halofuginone photoaffinity chemoproteomics with docking and proteomics [#6]

   PMID:38739798 PMID:38923255

   Open questions at the time

   • Halofuginone binding modeled by docking, not high-resolution structure
   • Direct causal link between the amino-acid metabolism proteome change and enzyme activity not established
   • Physiological substrates whose deubiquitination is blocked remain unidentified

• The endogenous ubiquitin/Nedd8 substrates and the specific cellular pathway whose disruption makes the enzyme essential remain undefined.
• No physiological substrate identified
• Relationship between deubiquitinase and deNeddylase functions in vivo unresolved
• Interactome/complex membership uncharacterized